- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01620242
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes (ORL03)
A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6 cycles.
In absence of progression disease or unacceptable toxicity, the treatment could be continued until a maximum of 10 cycles.
Disease response will be assessed every 6 weeks (i.e. every 2 cycles) clinically and by CT-scan.
An interim analysis will be carried out after the inclusion of the first 10 eligible and assessable patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59020
- Centre Oscar Lambret
-
Lyon, France, 69008
- Centre Léon Bérard
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Paris, France, 75231
- Institut Curie
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Metastatic or recurrent Head and neck cancer
- Progression after cisplatin, cetuximab and taxanes (drugs could have been administered alone or in combination) given for recurrent/metastatic disease
- Age ≥ 18
- ECOG performance status ≤ 2
- At least one measurable lesion on CT-scan (as per RECIST criteria V1.1).
- Life expectancy ≥ 3 months
- Adequate hematologic function (neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L; Hb ≥ 9.0 g/dL), renal function (clearance creatinine using the CKD-EPI formula (Chronic Kidney Disease Epidemiology group) ≥ 60 mL/min) and hepatic function (serum bilirubin ≤ 1 ULN; AST and ALT ≤ 2.5 x ULN).
- Potentially reproductive patients must agree to use an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 6 months after the final dose of investigational product.
- Women of childbearing potential must have a negative serum beta-HCG pregnancy test within 14 days prior of enrolment and/or urine pregnancy test within 48 hours before the first administration of the study treatment.
- Patients must be affiliated to a Social Security System.
- Patient who have received the information sheet and signed the informed consent form.
- Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
Exclusion Criteria:
- Active concurrent malignancy
- Progression in the 3 months after the completion of treatment for localized disease
Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as :
- infection,
- cardiac disease such as uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within one year, LVEF > grade 2,
- current active hepatic or biliary disease (with exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment),
- renal disease,
- active GI tract ulceration, malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with active, uncontrolled ulcerative colitis are also excluded,
- severely impaired lung function (spirometry and DLCO 70% or less of normal and O2 saturation of 88% or less at rest on room air).
- Patients must have recovered of previous toxicity of chemotherapy and must not have toxicity grade > 1 ; grade ≥ 2 for neuropathy and grade ≥ 2 for cutaneous rash after cetuximab (in the CTCAE v4.0)
- Hypersensitivity to cabazitaxel, to other taxanes, or to any excipients of the formulation including polysorbate 80
- Pregnant women, women who are likely to become pregnant or are breast-feeding.
- Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- Patients who received any other investigational drugs within the 14 days prior to the start of cabazitaxel.
- Patients receiving radiation within 4 weeks prior to the first dose of study drug.
- Patients already included in another therapeutic trial involving an experimental drug
- Individual deprived of liberty or placed under the authority of a tutor.
- Other primary tumors within the previous 3 years
- Concomitant prohibited treatment. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5. A one week wash-out period is necessary for patients who are already on these treatments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabazitaxel
All patients are treated with Cabazitaxel.
|
25 mg/m2 every 3 weeks by IV administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
non-progression at 6 weeks
Time Frame: 6 weeks
|
To assess the efficacy of cabazitaxel in terms of non-progression at 6 weeks for the treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes. Non-progression will be assessed after centralized review of CT-scans. |
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
progression free survival
Time Frame: 1-year
|
1-year
|
Toxicity according to NCI-CTCAE v4.0
Time Frame: from the first dose up to 30 days after the last dose
|
from the first dose up to 30 days after the last dose
|
Quality of life evaluated by the QLQ-C30 and H&N35 questionnaire
Time Frame: at the inclusion, at 6 weeks and at the end of treatment
|
at the inclusion, at 6 weeks and at the end of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UC-0130/1106
- 2011-004712-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Cancer
-
Merck Sharp & Dohme LLCCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Royal Marsden NHS Foundation TrustRecruitingRecurrent Head and Neck CancerUnited Kingdom
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States
-
University of Colorado, DenverCompletedRecurrent Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
-
University Hospital, Strasbourg, FranceNot yet recruitingRecurrent Head and Neck Cancer | Local Cryotherapy TreatmentFrance
Clinical Trials on Cabazitaxel
-
Jeffrey Yachnin M.D., PhD.SanofiCompletedMetastatic Castration Resistant Prostate CancerSweden
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiCompleted
-
Vejle HospitalSanofiTerminated
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalUnknown
-
Institut für Klinische Krebsforschung IKF GmbH...Completed
-
Gustave Roussy, Cancer Campus, Grand ParisSanofiUnknownNon-seminomatous Germ-cell TumorsFrance
-
Rambam Health Care CampusCompleted
-
University Hospitals Bristol and Weston NHS Foundation...SanofiCompletedPenile NeoplasmUnited Kingdom
-
Brown UniversityTerminated
-
European Organisation for Research and Treatment...SanofiCompletedDedifferentiated LiposarcomaUnited Kingdom, Belgium, France, Italy